Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr;68(4):627-631.
doi: 10.4103/ijo.IJO_1145_19.

Antibiotic sensitivity trends of pseudomonas endophthalmitis in a tertiary eye care center in South India: A 12-year retrospective study

Utsab Pan  1 , Aarti Jain  2 , Joseph Gubert  3 , Bibha Kumari  4 , Manavi D Sindal  5
Affiliations

Antibiotic sensitivity trends of pseudomonas endophthalmitis in a tertiary eye care center in South India: A 12-year retrospective study

Utsab Pan et al. Indian J Ophthalmol. 2020 Apr.

Abstract

Purpose: To assess trends in antibiotic sensitivity of pseudomonas and compare multidrug resistance (MDR) between Pseudomonas endophthalmitis cases presenting in two consecutive 6-year time frames in a tertiary center in South India.

Methods: This is a retrospective comparative series of all Pseudomonas endophthalmitis cases treated from June 2004 to May 2016. Microbiological culture results in all endophthalmitis patients were screened for pseudomonas. Positive cases in the initial 6 and final 6 years were compared for sensitivity to antibiotics and the proportion of MDR. MDR was defined as resistance to at least two different classes of antibiotics.

Results: Pseudomonas accounted for 74 of 389 endophthalmitis cases (19%), 42 in initial 6 and 32 in final 6 years. Sensitivity to ciprofloxacin, ofloxacin, gatifloxacin, moxifloxacin, and ceftazidime was 85.7%, 82.9%, 76.5%, 76.9%, 88.1% up to 2010 which reduced to 75%, 59.4%, 68.8%, 56.3%, 56.3%, respectively, after 2010, being significant for ofloxacin (P = 0.0349) and ceftazidime (P = 0.0028). Susceptibility to amikacin, gentamicin, and tobramycin changed non-significantly from 83.3%, 43.9%, 47.6% to 71.9%, 61.3%, 61.3%, respectively. Twenty of 74 cases (27%) were MDR with 16.7% in first 6 years versus 40.6% in final 6 years. Postoperative MDR cases rose from 10.3% to 50% (P = 0.0048).

Conclusion: This study shows rising resistance of Pseudomonas to fluoroquinolones, amikacin, and ceftazidime in endophthalmitis. MDR also showed an upward trend, particularly in postsurgical cases.

Keywords: Antibiotic sensitivity; multi-drug resistance; pseudomonas endophthalmitis.

PubMed Disclaimer

Conflict of interest statement

None

Figures

Figure 1
Figure 1
Comparison of antibiotic sensitivity between two postoperative endophthalmitis subgroups (Group 1A vs 2A). CH – Chloramphenicol, CA – Ceftazidime, CF – Ciprofloxacin, OF – Ofloxacin, MO – Moxifloxacin, GF – Gatifloxacin, AK – Amikacin, G – Gentamicin, TB – Tobramycin, CE – Cephotaxime
See this image and copyright information in PMC

References

    1. Han DP, Wisniewski SR, Wilson LA, Barza M, Vine AK, Doft BH, et al. Spectrum and susceptibilities of microbiologic isolates in the endophthalmitis vitrectomy study. Am J Ophthalmol. 1996;122:1–17. - PubMed
    1. Anand AR, Therese KL, Madhavan HN. Spectrum of aetiological agents of postoperative endophthalmitis and antibiotic susceptibility of bacterial isolates. Indian J Ophthalmol. 2000;48:123–8. - PubMed
    1. Pathengay A, Moreker MR, Puthussery R, Ambatipudi S, Jalali S, Majji AB, et al. Clinical and microbiologic review of culture-proven endophthalmitis caused by multidrug-resistant bacteria in patients seen at a tertiary eye care center in southern India. Retina. 2011;31:1806–11. - PubMed
    1. Eifrig CW, Scott IU, Flynn HW, Miller D. Endophthalmitis caused by Pseudomonas aeruginosa. Ophthalmology. 2003;110:1714–7. - PubMed
    1. Collee JG, Fraser AG, Simmons A, Marmion BP. Mackie and McCartney Practical Medical Microbiology. 14th ed. Elsevier; 1996. pp. 413–8. South Asia Edition Chapter 23.

MeSH terms

Substances